New Enterprise Associates made the most venture deals for the second year in a row in 2017, with 125 investments totaling $914 million, according to VCJ’s analysis of preliminary Thomson Reuters data through mid-December.
Precision Medicine Group announced it had raised $275 million. The round was led by Berkshire Partners and TPG Growth, with participation from its co-founders and management team, as well as original investors Oak Investment Partners and J.H. Whitney.
When the University System of Maryland set its strategic plan for the next 10 years in 2010, it hoped to double the system’s externally sponsored research and development funding from $1.2 billion to $2.4 billion. Instead, as federal dollars have dried up, that number has remained relatively flat, up to just $1.27 billion with three years
Global pharmaceutical company Mallinckrodt Plc (NYSE: MNK) has entered an agreement to buy Rockville’s Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) for $1.2 billion including debt.
Shanghai-based pharmaceutical company WuXi AppTec Group is partnering with Merck Serono, a subsidiary of company Merck KGaA, to launch a pharma and biotech startup incubator in Israel in early 2018. Israel-born businessman Mori Arkin and life sciences-focused venture capital fund Pontifax Ltd. will also be part of the venture. The plans were declared last week in an event held by the partners in Tel Aviv.
Swiss pharma giant Roche has given itself a pricey holiday gift and deepened its oncology product portfolio with its $1.7 billion acquisition of immuno-oncology business Ignyta. Based in San Diego, the company tests, identifies, and treat patients with cancers that come with rare mutations.
While 2016 was marked by a changing landscape as the city’s tech community expanded into new neighborhoods, 2017 was defined by moves from the companies themselves.
In a buyout that marks the latest endorsement for targeted cancer drugs—and, potentially, the increasing utility of broad cancer DNA tests—Roche this morning agreed to acquire San Diego biotech Ignyta in an all-cash deal valued at $1.7 billion.
Sisu is hiring in Baltimore and Ghana. Sisu is a medical device company for emerging markets and these hires will play an integral role as we launch Hemafuse in Ghana and Kenya. Hemafuse is a device that can salvage and recycle a person’s own blood from internal bleeding. Sisu is seeking a baltimore-based Program Manager and Production Manager (posting soon). We are also hiring a Ghana-based Marketing manager and Africa-based Sales director. Click on the blog post to see more!
Application deadlines:
JANUARY 15, 2018 for New Applications
FEBRUARY 5, 2018 for Re-submissions
APRIL 5, 2018 for Grant Submission
As part of your application, you will need to complete and upload a one page abstract as well as upload your curriculum vitae (CV). Please download the abstract guidelines and provide your abstract in the requested format. You will be able to upload additional supporting documents once your application has been submitted by following the link that will arrive in your confirmation email.